U.S. Marine and Shipping Stock News

NYSE:AWI
NYSE:AWIBuilding

A Look At Armstrong World Industries (AWI) Valuation After 2025 Results And 2026 Earnings Guidance

Why Armstrong World Industries is on investors’ radar right now Armstrong World Industries (AWI) has attracted fresh attention after releasing fourth quarter and full year 2025 results alongside earnings guidance for 2026, giving investors new data on both recent performance and management expectations. See our latest analysis for Armstrong World Industries. The recent guidance for 2026, dividend affirmation and senior leadership change come as the share price has pulled back, with a 7 day...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

AeroVironment (AVAV) Is Down 20.3% After Landing $186 Million Army Switchblade Order - Has The Bull Case Changed?

In late February 2026, AeroVironment announced a US$186 million delivery order from the U.S. Army for its next-generation Switchblade 600 Block 2 and Switchblade 300 Block 20 loitering munitions under an existing five-year, US$990 million IDIQ contract for Lethal Unmanned Systems. This marks the Army’s first procurement of AeroVironment’s upgraded Switchblade line featuring explosively formed penetrator payloads and enhanced anti-armor capabilities, reinforcing the company’s role in...
NasdaqGS:IDYA
NasdaqGS:IDYABiotechs

Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy?

IDEAYA Biosciences recently enrolled the first patient in a Phase 1 trial of IDE034, a bispecific TOP1 antibody-drug conjugate targeting co-expressed PTK7 and B7H3 in solid tumors, triggering a US$5.00 million milestone payment to Biocytogen under their Option and License Agreement. The trial positions IDE034 as a potentially first-in-class asset with a co-expression-based targeting approach and combination plans with IDEAYA’s PARG inhibitor IDE161, aimed at enhancing selectivity and...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

How iTero–Henry Schein One Integration and New Bylaws Will Impact Align Technology (ALGN) Investors

In February 2026, Henry Schein One announced a direct data integration between Align Technology’s iTero intraoral scanners and its Dentrix, Dentrix Ascend, and Dentally practice management platforms, while Align’s board separately adopted amended and restated bylaws allowing long-term holders of at least 25% of its shares to request special shareholder meetings. Together, the deeper integration of iTero into one of dentistry’s largest software ecosystems and the expanded shareholder meeting...
NYSE:DIS
NYSE:DISEntertainment

Assessing Disney (DIS) Valuation As Recent Share Weakness Meets Conflicting Undervaluation Signals

Recent Performance Snapshot Walt Disney (DIS) has seen mixed share performance recently, with about a 1.6% decline over the past day, flat movement over the past week, and a larger decline over the past month. See our latest analysis for Walt Disney. Looking beyond the recent weakness, the 1 year total shareholder return is a decline of 6.5%, while the 3 year total shareholder return is a gain of 6.1%. This suggests sentiment has been improving over a longer stretch, even as the current share...
NYSE:CHD
NYSE:CHDHousehold Products

Assessing Church & Dwight (CHD) Valuation After Recent Share Price Momentum And Mixed Return Profile

Why Church & Dwight is on investors’ radar today Church & Dwight (CHD) is drawing fresh attention after a period in which the share price and fundamentals have moved in different directions, prompting investors to reassess how the business is currently priced. The stock has returned about 8% over the past month and roughly 24% in the past 3 months, while the 1 year total return is a 6% decline. That split between recent momentum and longer term performance often leads investors to look more...
NYSE:ABBV
NYSE:ABBVBiotechs

AbbVie Expands Rare Oncology And Immunology With New U.S. Manufacturing Investment

AbbVie (NYSE:ABBV) received FDA orphan drug designation for a neuroendocrine carcinoma treatment. The company reported positive Phase 3 results for risankizumab in Crohn's disease. AbbVie announced a $380 million investment in new U.S. manufacturing facilities using advanced technologies and AI. AbbVie, trading at $234.26, has seen its share price move alongside a 14.5% return over the past year and a 167.3% return over the past five years. These recent updates touch three key areas...
NYSE:FR
NYSE:FRIndustrial REITs

Is Activist Land & Buildings’ Boardroom Challenge Altering The Investment Case For First Industrial Realty Trust (FR)?

In February 2026, activist investor Land & Buildings intensified pressure on First Industrial Realty Trust by publicly criticizing the board’s culture, urging governance and portfolio changes, and formally nominating its founder Jonathan Litt for election at the 2026 annual shareholder meeting. This push for boardroom reform comes just after First Industrial reported quarterly earnings and revenue that significantly exceeded analyst expectations, sharpening attention on how governance...
NasdaqGS:HSIC
NasdaqGS:HSICHealthcare

Assessing Henry Schein (HSIC) Valuation After Recent Share Price Momentum

Why Henry Schein is on investors' radar today Henry Schein (HSIC) has drawn fresh attention after its recent trading performance, with the shares closing at $81.37 and showing positive returns over the past month and the past three months. See our latest analysis for Henry Schein. While the share price saw a 1 day decline of 1.24%, Henry Schein’s 30 day share price return of 7.80% and 1 year total shareholder return of 14.91% suggest momentum has been building recently rather than fading. If...
NYSE:ALG
NYSE:ALGMachinery

Assessing Alamo Group (ALG) Valuation After Weaker 2025 Earnings And Strong Recent Share Gains

Why the latest earnings matter for Alamo Group (ALG) Alamo Group (ALG) drew fresh attention after reporting fourth quarter and full year 2025 results, showing lower sales and net income than the prior year. This combination can reshape how investors think about the stock. See our latest analysis for Alamo Group. Despite the weaker 2025 earnings print, Alamo Group’s share price has been strong, with a 90 day share price return of 34.94% and a 1 year total shareholder return of 24.93%. This...
NasdaqGS:CCEC
NasdaqGS:CCECShipping

Should Capital Clean Energy Carriers’ €250 Million Bond and 2025 Results Timing Require Action From CCEC Investors?

Capital Clean Energy Carriers Corp. recently priced a €250 million unsecured bond issue in Greece, maturing in 2033 with a 3.75% semi-annual coupon, and has also announced that its fourth-quarter 2025 financial results will be released on March 5, 2026. The bond proceeds earmarked for debt repayment, capital expenditure and working capital shed light on how CCEC is reshaping its balance sheet and funding future growth projects. We’ll explore how this €250 million unsecured bond issuance may...
NYSE:DTM
NYSE:DTMOil and Gas

What DT Midstream (DTM)'s Strong 2025 Results and Bigger Project Pipeline Mean For Shareholders

DT Midstream, Inc. reported full-year 2025 results showing sales rising to US$1,243 million and net income to US$441 million, alongside a 7% dividend increase to US$0.88 per share and a US$396.99 million shelf registration for 3,000,000 shares related to its ESOP. Management’s disclosure that its project pipeline is several times larger than the announced US$3.40 billion capital plan, with growth expected to outpace a 7% annualized rate through the rest of the decade, points to a materially...
NasdaqGS:MELI
NasdaqGS:MELIMultiline Retail

MercadoLibre (MELI) Valuation After Earnings Miss And Margin Pressure From Heavy Growth Investments

Why MercadoLibre’s earnings triggered such a strong stock reaction MercadoLibre (MELI) reported fourth quarter 2025 revenue of US$8.76b and net income of US$559m, a result that paired strong business activity with higher spending and thinner margins. For the full year 2025, revenue reached US$28.89b and net income was US$1.997b, with earnings per share from continuing operations at US$39.40 on both a basic and diluted basis. See our latest analysis for MercadoLibre. MercadoLibre’s recent...
NYSE:SGHC
NYSE:SGHCHospitality

Super Group (SGHC) Is Up 13.4% After Strong 2025 Results And Higher Dividend Guidance

Super Group (SGHC) Limited recently reported strong fourth-quarter and full-year 2025 results, lifting annual revenue from US$1.80 billion in 2024 to US$2.20 billion, while guiding for 2026 revenue above US$2.55 billion and confirming plans to raise its annual dividend program target to a minimum of US$0.20 per share, payable quarterly from March 31, 2026. An interesting aspect is how broad-based regional growth across Europe, Asia-Pacific, Africa, and North America is coinciding with a...
NYSE:PSN
NYSE:PSNProfessional Services

Assessing Parsons (PSN) Valuation After Bastion Asset Management’s New Fourth Quarter Stake

Institutional Buying Puts Parsons in Focus Bastion Asset Management’s new fourth quarter position in Parsons (PSN), totaling 128,186 shares worth about US$8.04 million, has put fresh attention on the contractor’s government and infrastructure exposure. See our latest analysis for Parsons. Parsons’ share price closed at US$67.86 after a 2.82% 1 day share price return. Despite an 18.12% 90 day share price decline, the 1 year total shareholder return of 22.60% and 5 year total shareholder return...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Viridian Therapeutics (VRDN) Valuation After Wider Q4 Loss And Ongoing Thyroid Eye Disease Regulatory Reviews

Viridian Therapeutics (VRDN) is in focus after reporting a larger than expected Q4 2025 loss and lower than forecast revenue. Its lead thyroid eye disease candidate remains under FDA Priority Review and EMA review. See our latest analysis for Viridian Therapeutics. At a share price of US$30.25, Viridian’s 1 day share price return of 2.96% and 7 day share price return of 7.77% follow a weaker 30 day share price return of an 8.33% decline. The 1 year total shareholder return of 109.92%...
NYSE:OI
NYSE:OIPackaging

Why O-I Glass (OI) Is Down 8.9% After Major Hedge Fund Sale Amid Higher 2026 EBITDA Target

In the past quarter, Cooper Creek Partners Management disclosed it sold 6,030,588 O-I Glass shares for an estimated US$79.78 million, while management highlighted ongoing multi-year margin rebuilding with improving cash flow and expanding segment operating profit. Alongside this large institutional sale, O-I Glass now guides for US$1.25 billion to US$1.30 billion in adjusted EBITDA in 2026 despite a projected US$150 million energy cost headwind, underscoring management’s confidence in its...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

Assessing Flywire (FLYW) Valuation After Q4 Beat And Upbeat 2026 Guidance

Flywire (FLYW) has been in focus after Q4 2025 results topped Wall Street estimates on both revenue and earnings, and management paired that with upbeat 2026 guidance for FX neutral revenue less ancillary services growth. See our latest analysis for Flywire. The upbeat Q4 2025 release and 2026 guidance arrived after a mixed stretch for Flywire, with a 16.8% 7 day share price return contrasting with a 10.6% year to date decline and a 55.3% 3 year total shareholder return loss. The recent move...
NYSE:RVTY
NYSE:RVTYLife Sciences

Reassessing Revvity (RVTY) Valuation After Prolonged Share Price Weakness

Revvity (RVTY) has recently drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month, past 3 months and year. See our latest analysis for Revvity. With the share price at $95.59 and a 30 day share price return of 12.14% decline, recent weakness builds on a softer trend, as the 1 year total shareholder return of 13.16% decline and 3 year total shareholder return of 25.03% decline point to fading momentum despite...
NYSE:HLIO
NYSE:HLIOMachinery

Assessing Helios Technologies (HLIO) Valuation After Strong Results And Fresh 2026 Revenue Guidance

Why Helios Technologies Stock Is Back in Focus Helios Technologies (HLIO) is on investors’ radar after issuing fresh 2026 revenue guidance alongside its latest earnings. The company outlined expected sales ranges for both the first quarter and the full fiscal year. See our latest analysis for Helios Technologies. The guidance and earnings update have arrived alongside strong share price momentum, with a 39.6% 3 month share price return and a 99.9% 1 year total shareholder return, suggesting...
NYSE:DTE
NYSE:DTEIntegrated Utilities

The Bull Case For DTE Energy (DTE) Could Change Following Back-to-Back Rate Hike Requests Amid Pushback

DTE Energy reported past full-year 2025 results with revenue of US$15.81 billion and net income of US$1.46 billion, alongside confirming 2026 operating EPS guidance of US$7.59–US$7.73. Soon after regulators approved a US$242.2 million electric rate hike, DTE moved to pursue yet another increase, drawing sharp criticism from Michigan’s Attorney General and consumer groups concerned about customer costs amid record profit projections. Against this backdrop of back-to-back rate hike requests,...
NasdaqGS:CORZ
NasdaqGS:CORZSoftware

What Core Scientific (CORZ)'s Q4 Profit Amid Full‑Year Loss Means For Its AI Pivot

Core Scientific, Inc. has reported its fourth‑quarter and full‑year 2025 results, with quarterly revenue of US$79.76 million and net income of US$215.96 million, alongside lower full‑year revenue of US$319.02 million and a full‑year net loss of US$288.62 million. The shift from a prior net loss to quarterly profitability, supported by reduced impairments of property, plant and equipment to US$11.36 million, underscores the operational impact of Core Scientific’s move toward AI‑focused data...
NasdaqGS:LGIH
NasdaqGS:LGIHConsumer Durables

Assessing LGI Homes' (LGIH) Valuation After The Meadow Brook Community Launch In Washington

Why Meadow Brook matters for LGI Homes stock LGI Homes (LGIH) has opened its Meadow Brook community in Puyallup, Washington, adding 53 upgraded homes with energy efficient features in a sought after area near Tacoma and the broader Seattle market. For you as a shareholder or prospective investor, this new community offers a concrete example of how LGI Homes is allocating capital into specific local markets, price points and product features. These decisions can influence future home closing...
NasdaqGM:PAYO
NasdaqGM:PAYODiversified Financial

A Look At Payoneer Global (PAYO) Valuation As Q4 Miss And 2026 Outlook Pressure Sentiment

Payoneer Global (PAYO) is back in focus after fourth quarter 2025 results and 2026 guidance came in below analyst expectations, pressuring the stock and putting its profitability focused playbook under the microscope. See our latest analysis for Payoneer Global. Those weaker fourth quarter numbers and cautious 2026 guidance have come after a tough stretch, with a 30 day share price return of 28.33% decline and a 1 year total shareholder return of 45.15% decline pointing to fading momentum...